Reimbursement for erythropoiesis-stimulating agents poses challenges.
Traynor
Kate
K
D000554:Ambulatory Care Facilities / Q000191:economics; D000740:Anemia / Q000188:drug therapy; D000068256:Darbepoetin alfa; D004348:Drug Labeling; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D006397:Hematinics / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D012051:Reimbursement Mechanisms / Q000458:organization & administration*
D006397:Hematinics; D004921:Erythropoietin; D000068256:Darbepoetin alfa